GlassScriptPhysician profile
Saif Rehman
NPI 1386747798
$1,314.54
in general payments reported to CMS, 2019-2025
19 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $25.82 · 2021: $66.62 · 2022: $216 · 2023: $231 · 2024: $258 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $215.59 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $171.77 | 2022-2024 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $161.14 | 2021-2024 | Veltassa |
| Baxter Healthcare | $127.88 | 2021-2024 | Renal - Pd |
| Vantive US Healthcare LLC | $115.94 | 2025 | Renal - Pd |
| Glaxosmithkline, LLC. | $88.25 | 2021-2023 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $64.09 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $63.12 | 2023-2025 | Korsuva, Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $56.72 | 2020-2025 | Terlivaz |
| Travere Therapeutics, INC. | $55.21 | 2022-2023 | |
| Nxstage Medical, INC. | $44.79 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.31 | 2025 | |
| Akebia Therapeutics INC | $23.11 | 2019-2021 | |
| Amgen INC. | $20.03 | 2025 | Uplizna |
| Novo Nordisk INC | $16.48 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $15.00 | 2024 | Purified Cortrophin Gel |
| Ardelyx, INC. | $14.21 | 2025 | Ibsrela |
| Cormedix INC. | $13.55 | 2025 | Defencath |
| Genentech USA, INC. | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saif Rehman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.